Myriad Genetics, Inc. MYGN

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5% in the afternoon session after Craig-Hallum analyst John Wilkin raised the firm's price target on the stock to $8, StreetInsider reported.

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

Over the past six months, Myriad Genetics’s stock price fell to $4.01. Shareholders have lost 13% of their capital, which is disappointing considering the S&P 500 has climbed by 18.4%. This was partly due to its softer quarterly results and might have investors contemplating their next move.

Quest Diagnostics (NYSE:DGX) CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions. D

Myriad Genetics is back in focus after a sharp reset in analyst price targets, with the modelled fair value estimate moving from about US$6.25 to roughly US$3.37, a cut of close to 46%. The shift lines up with more cautious Street commentary that concentrates on execution risk, profitability, and the impact of reduced FY26 guidance on how the stock is valued. As you read on, you will see how to interpret these updates and how to follow the evolving narrative around Myriad Genetics. Stay...

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026. Vishal has served as the SVP of Product at Myriad for the past year. He has deep understanding of molecular diagnostics and oncology as well as extensive business and commercial leadership experience from his prior roles

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers.

Check out the companies making headlines yesterday:

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 6.2% in the afternoon session after Piper Sandler double-downgraded the stock to Underweight, stating that major strategic action is likely needed.

Piper Sandler cuts Myriad Genetics stock to Underweight, citing doubts about the genetic testing company’s path to sustainable profitability.

Myriad Genetics (NASDAQ:MYGN) shares fell 7. 1% in pre-market trading to $2.

SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST. The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at investor.myriad.com. About Myriad Genetics Myriad Genetics is

A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders continued to secure profits following the extraordinary run. The sector had jumped after Phase 3 results for Moderna’s individualized neoantigen mRNA therapy, intismeran, used with Merck’s Keytruda — the first positive late-stage readout for an mRNA-based cancer vaccine over Keytruda alone. With no fresh clinical or regulatory catalyst to extend the advance, the tape has shifted